14 Sep 2024 Avacta Reports Updated Phase 1 Clinical Data of AVA6000 at the European Society for Medical Oncology (ESMO) Congress Demonstrating Multiple Ongoing, Durable Responses in Solid Tumors Investors | Therapeutics
11 Sep 2024 Research & Development Spotlight Series – Episode 5 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
09 Sep 2024 Avacta to present updated clinical data on AVA6000 at the European Society for Medical Oncology (ESMO) Congress Investors | Therapeutics
12 Aug 2024 Research & Development Spotlight Series – Episode 4 Blogs | Podcasts and Videos | R&D Spotlights Series | Therapeutics
03 Jun 2024 Research & Development Spotlight Series – Episode 3 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
23 May 2024 Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta’s AVA6000 Phase 1 trial Investors | Therapeutics
25 Apr 2024 Research and Development Spotlight Series – Episode 2 Blogs | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics
09 Apr 2024 Christina Coughlin – AACR 2024 – AVA6000 data presentation Blogs | Investors | Podcasts and Videos | Therapeutics
09 Apr 2024 Avacta Therapeutics Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 at the AACR Annual Meeting Demonstrating Clinical Proof-of-Concept Showing Multiple Patient Responses Investors | Therapeutics